ORIC Pharmaceuticals, Inc.

107 articles about ORIC Pharmaceuticals, Inc.

• ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 02, 2023

  6/2/2023

  ORIC Pharmaceuticals, Inc. announced that on June 1, 2023, ORIC granted a total of 3,380 non-qualified stock options and 560 restricted stock units to one new non-executive employee who began their employment with ORIC in May 2023.

• ORIC Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

  5/31/2023

  ORIC Pharmaceuticals, Inc. announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 10:00 a.m. ET.

• ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

  5/8/2023

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2023.

• ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  5/5/2023

  ORIC Pharmaceuticals, Inc. today announced that on May 1, 2023 (the “Grant Date”), ORIC granted a total of 29,800 non-qualified stock options and 4,980 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2023.

• ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

  4/25/2023

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.

• ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

  4/18/2023

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented two preclinical poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

• ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

  3/16/2023

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter and year ended December 31, 2022.

• ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting

  3/14/2023

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that two abstracts have been accepted for poster presentations at the 2023 American Association for Cancer Research Annual Meeting taking place April 14-19, 2023, in Orlando, FL.

• ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference

  3/6/2023

  ORIC Pharmaceuticals, Inc. today announced that management will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 2:00 p.m. ET.

• ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 03, 2023

  2/3/2023

  ORIC Pharmaceuticals, Inc. announced that on February 1, 2023, ORIC granted a total of 35,596 non-qualified stock options and 5,948 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2023.

• ORIC Pharmaceuticals to Participate in Upcoming February 2023 Investor Conferences

  2/1/2023

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in February.

• ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones - January 9, 2023

  1/9/2023

  ORIC Pharmaceuticals, Inc. today provided program updates and announced upcoming key milestones.

• ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 11:15 a.m. PT.

• ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

  12/21/2022

  ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) today announced that it has entered into a clinical development collaboration for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer and agreed to sell 5,376,344 of its common shares at a price of $4.65 per share to Pfizer for proceeds of approximately $25.0 million.

• ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting

  12/13/2022

  ORIC Pharmaceuticals, Inc. presented preclinical ORIC-533 data demonstrating a potential best-in-class CD73 inhibitor profile for the treatment of multiple myeloma.

• ORIC Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference

  11/8/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 5:35 p.m. GMT.

• ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update

  11/7/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended September 30, 2022.

• ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting

  11/3/2022

  ORIC Pharmaceuticals, Inc. announced a preclinical poster presentation on ORIC-533 at the 64th American Society of Hematology Annual Meeting to be held December 10-13, 2022, in New Orleans, LA.

• ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 07, 2022

  10/7/2022

  ORIC Pharmaceuticals, Inc. announced that on October 3, 2022, ORIC granted a total of 116,560 non-qualified stock options and 19,435 restricted stock units to five new non-executive employees who began their employment with ORIC in September 2022.

• ORIC Pharmaceuticals to Participate in Upcoming September 2022 Investor Conferences

  9/1/2022

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in September.